Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies targeting galectin proteins, especially galectin-3, to treat fibrotic diseases, cancer, and inflammatory conditions. Its lead candidate, belapectin, aims to reverse liver fibrosis and prevent complications in NASH cirrhosis. The company leverages proprietary carbohydrate-based compounds, conducts clinical trials, and seeks strategic partnerships to advance its innovative, patent-protected drug development pipeline.
This description was generated via AI from an annual report. Updated about 1 year ago.